In this episode, we review findings from the Japan subset of the DUO-E phase III trial, led by Shin Nishio and colleagues, which evaluated durvalumab with or without olaparib following chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. The study demonstrated a progression-free survival benefit in Japanese patients consistent with the global population, with a median of 15.1 months in the durvalumab plus olaparib arm compared to 9.5 months in the control arm. Safety outcomes were manageable and aligned with known profiles of the treatments. These results support durvalumab-based regimens as promising first-line options for Japanese patients.